Research Topic: hallucinogens

Drug–drug interactions involving classic psychedelics: A systematic review

mycolabadmin

This review examined how psychedelic drugs like LSD and psilocybin interact with other medications people might be taking. Researchers found that certain psychiatric medications like antipsychotics can block the effects of psychedelics, while other drugs may enhance them. The study highlights the importance of understanding these interactions for safe therapeutic use of psychedelics in clinical settings.

Read More »

New perspective on sustained antidepressant effect: focus on neurexins regulating synaptic plasticity

mycolabadmin

This review explores how hallucinogens like ketamine and psilocybin produce long-lasting antidepressant effects by changing how brain cells communicate. The key mechanism involves special molecules called neurexins that sit at the connections between neurons and control whether those connections strengthen or weaken. By understanding and potentially targeting neurexins, scientists hope to develop new depression treatments that work longer and more effectively than current medications.

Read More »

Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans

mycolabadmin

This comprehensive review examines how scientists use advanced imaging techniques like PET and SPECT scans to study how hallucinogenic drugs such as LSD and psilocybin interact with the brain. The research shows these drugs primarily bind to serotonin receptors, particularly the 5-HT2A subtype, which appear responsible for producing hallucinations. While scientific understanding of hallucinogen mechanisms has advanced significantly, there is still much to learn about their complete effects on brain chemistry and their potential therapeutic applications.

Read More »

Psychedelics action and schizophrenia

mycolabadmin

This review examines how psychedelic drugs like psilocybin and LSD affect the brain, particularly through serotonin receptors. While these compounds can produce psychosis-like symptoms similar to schizophrenia, they also promote brain plasticity and growth of neural connections. The article discusses whether psychedelics could potentially treat negative symptoms and cognitive problems in schizophrenia patients, despite their mind-altering properties, possibly through lower doses or non-hallucinogenic alternatives.

Read More »

Lower-dose psycholytic therapy – A neglected approach

mycolabadmin

This review examines psycholytic therapy, a method using lower doses of LSD or psilocybin combined with ongoing psychotherapy to help people process psychological conflicts and trauma. Developed in Europe during the 1960s-1970s and used successfully at over 30 clinics, this approach was largely abandoned when psychedelics became illegal but is now being reconsidered. Historical research shows it was effective for anxiety, depression, and personality issues in treatment-resistant patients, with safety profiles comparable to conventional therapy.

Read More »

Scoping Review: The Role of Psychedelics in the Management of Chronic Pain

mycolabadmin

This review examines how psychedelic drugs like LSD and psilocybin might help treat chronic pain conditions such as cluster headaches and phantom limb pain. The researchers found nine studies suggesting these substances could reduce pain by affecting serotonin receptors in the brain. While early results are promising, more rigorous clinical trials are needed before these drugs can become standard pain treatments. The authors note that strict legal restrictions on psychedelics currently limit research opportunities.

Read More »
Scroll to Top